A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Shapira-Frommer, R; Oza, A; Domchek, SM; Balmana, J; Patel, MR; Chen, LM; Drew, Y; Burris, HA; Korach, J; Flynn, M; Bowering, VL; Morgan, MA; Watkins, SP; Simpson, D; Goble, S; Maloney, L; Kristeleit, R

doi:10.1016/S0959-8049(16)31512-X

A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Lookup NU author(s): Dr Yvette Drew ORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Publication metadata

Author(s): Shapira-Frommer R, Oza A, Domchek SM, Balmana J, Patel MR, Chen LM, Drew Y, Burris HA, Korach J, Flynn M, Bowering VL, Morgan MA, Watkins SP, Simpson D, Goble S, Maloney L, Kristeleit R

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: European Cancer Congress 2015

Year of Conference: 2015

Pages: S545

Print publication date: 01/09/2015

Online publication date: 08/02/2016

Acceptance date: 01/01/1900

ISSN: 0959-8049

Publisher: Elsevier

URL: http://dx.doi.org/10.1016/S0959-8049(16)31512-X

DOI: 10.1016/S0959-8049(16)31512-X

Series Title: European Journal of Cancer

ePrints

A Phase 2 open-label, multicenter study of single-agent rucaparib in the treatment of patients with relapsed ovarian cancer and a deleterious BRCA mutation

Downloads

Publication metadata

Share